DNAzymes and cardiovascular disease

British Journal of Pharmacology

Volumn 154, Issue 4, 2008, Pages 741-748

  Benson, V L ^a,b   Khachigian, L M ^a,b   Lowe, H C ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Acute myocardial infarction; DNAzymes; Gene silencing; Gene targeting; Ischaemia reperfusion injury; Neointima formation

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; DNA; EARLY GROWTH RESPONSE FACTOR 1; ENZYME; MESSENGER RNA; NUCLEASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; ZINC FINGER PROTEIN;

ACUTE HEART INFARCTION; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CATALYSIS; ENZYME ACTIVITY; GENE SILENCING; GENE TARGETING; HEART FAILURE; HUMAN; INTIMA; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; REPERFUSION INJURY; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOVASCULAR DISEASES; DNA, CATALYTIC; GENE SILENCING; GENE TARGETING; GENE THERAPY; HUMANS;

EID: 44949193742     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.145     Document Type: Review

References (63)

1. Abdelgany A, Wood M, Beeson D (2007). Hairpin DNAzymes: a new tool for efficient cellular gene silencing. J Gene Med 9: 727-738.
2. Alexander SPH, Mathie A, Peters JA (2007). Guide to Receptors and Channels (GRAC). 2nd edn. (2007 revision) B J Pharmacol 150 (Suppl 1): S1-S168.
3. Bhindi R, Fahmy RG, Lowe HC, Chesterman CN, Dass CR, Cairns MJ et al. (2007). Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol 171: 1079-1088.
4. Bhindi R, Khachigian LM, Lowe HC (2006). DNAzymes targeting the transcription factor Egr-1 reduce myocardial infarct size following ischemia-reperfusion in rats. J Thromb Haemost 4: 1479-1483.
5. Biesiada E, Razandi M, Levin ER (1996). Egr-1 activates basic fibroblast growth factor transcription. Mechanistic implications for astrocyte proliferation. J Biol Chem 271: 18576-18581.
6. Bonventre JV, Sukhatme VP, Bamberger M, Ouellette AJ, Brown D (1991). Localization of the protein product of the immediate early growth response gene, Egr-1, in the kidney after ischemia and reperfusion. Cell Regul 2: 251-260.
7. Brand T, Sharma HS, Fleischmann KE, Duncker DJ, McFalls EO, Verdouw PD et al. (1992). Proto-oncogene expression in porcine myocardium subjected to ischemia and reperfusion. Circ Res 71: 1351-1360.
8. Breaker RR, Joyce GF (1994). A DNA enzyme that cleaves RNA. Chem Biol 1: 223-229.
9. Cairns MJ, Saravolac EG, Sun LQ (2002). Catalytic DNA: a novel tool for gene suppression. Curr Drug Targets 3: 269-279.
10. Chen Y, Lui VC, Rooijen NV, Tam PK (2004). Depletion of intestinal resident macrophages prevents ischaemia reperfusion injury in gut. Gut 53: 1772-1780.
11. Crooke ST (2004). Antisense strategies. Curr Mol Med 4: 465-487.
12. Dass CR, Saravolac EG, Li Y, Sun LQ (2002). Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev 12: 289-299.
13. Eckstein F (2007). The versatility of oligonucleotides as potential therapeutics. Expert Opin Biol Ther 7: 1021-1034.
14. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM (2003). Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 9: 1026-1032.
15. Fahmy RG, Khachigian LM (2004). Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth. Nucleic Acids Res 32: 2281-2285.
16. Fahmy RG, Khachigian LM (2007). Suppression of growth factor expression and human vascular smooth muscle cell growth by small interfering RNA targeting EGR-1. J Cell Biochem 100: 1526-1535.
17. Fahmy RG, Waldman A, Zhang G, Mitchell A, Tedla N, Cai H et al. (2006). Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. Nat Biotechnol 24: 856-863.
18. Fiammengo R, Jaschke A (2005). Nucleic acid enzymes. Curr Opin Biotechnol 16: 614-621.
19. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC et al. (2007). Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115: 2435-2441.
20. Fluiter K, ten Asbroek AL, de Wissel MB, Jakobs ME, Wissenbach M, Olsson H et al. (2003). In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res 31: 953-962.
21. Fox CS, Coady S, Sorlie PD, D'Agostino Sr RB, Pencina MJ, Vasan RS et al. (2007). Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115: 1544-1550.
22. Gashler A, Sukhatme VP (1995). Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol 50: 191-224.
23. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA (1995). Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 270: 2620-2627.
24. Huang RP, Fan Y, Boynton AL (1999). UV irradiation upregulates Egr-1 expression at transcription level. J Cell Biochem 73: 227-236.
25. Iversen PO, Nicolaysen G, Sioud M (2001). DNA enzyme targeting TNF-alpha mRNA improves hemodynamic performance in rats with postinfarction heart failure. Am J Physiol Heart Circ Physiol 281: H2211-H2217.
26. Khachigian LM (2000). Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. J Clin Invest 106: 1189-1195.
27. Khachigian LM (2001). Catalytic oligonucleotides targeting EGR-1 as potential inhibitors of in-stent restenosis. Ann N Y Acad Sci 947: 412-415.
28. Khachigian LM, Fahmy RG, Zhang G, Bobryshev YV, Kaniaros A (2002). c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. J Biol Chem 277: 22985-22991.
29. Khachigian LM, Lindner V, Williams AJ, Collins T (1996). Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science 271: 1427-1431.
30. Khachigian LM, Williams AJ, Collins T (1995). Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells. J Biol Chem 270: 27679-27686.
31. Kramer B, Meichle A, Hensel G, Charnay P, Kronke M (1994). Characterization of an Krox-24/Egr-1-responsive element in the human tumor necrosis factor promoter. Biochim Biophys Acta 1219: 413-421.
32. Libby P, Sukhova G, Lee RT, Galis ZS (1995). Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 25 (Suppl 2): S9-S12.
33. Liu C, Yao J, de Belle I, Huang RP, Adamson E, Mercola D (1999). The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1. J Biol Chem 274: 4400-4411.
34. Lowe HC, Chesterman CN, Khachigian LM (2002). Catalytic antisense DNA molecules targeting Egr-1 inhibit neointima formation following permanent ligation of rat common carotid arteries. Thromb Haemost 87: 134-140.
35. Lowe HC, Fahmy RG, Kavurma MM, Baker A, Chesterman CN, Khachigian LM (2001). Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. Circ Res 89: 670-677.
36. Lu ZX, Ye M, Yan GR, Li Q, Tang M, Lee LM et al. (2005). Effect of EBV LMP1 targeted DNAzymes on cell proliferation and apoptosis. Cancer Gene Ther 12: 647-654.
37. Lyn D, Liu X, Bennett NA, Emmett NL (2000). Gene expression profile in mouse myocardium after ischemia. Physiol Genomics 2: 93-100.
38. Mark DB, Van de Werf FJ, Simes RJ, White HD, Wallentin LC, Califf RM et al. (2007). Cardiovascular disease on a global scale: defining the path forward for research and practice. Eur Heart J 28: 2678-2684.
39. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S (1998). Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 98: 149-156.
40. Raymond SU, Leeder S, Greenberg HM (2006). Obesity and cardiovascular disease in developing countries: a growing problem and an economic threat. Curr Opin Clin Nutr Metab Care 9: 111-116.
41. Rockwell P, O'Connor WJ, King K, Goldstein NI, Zhang LM, Stein CA (1997). Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 94: 6523-6528.
42. Santiago FS, Atkins DG, Khachigian LM (1999a). Vascular smooth muscle cell proliferation and regrowth after mechanical injury in vitro are Egr-1/NGFI-A-dependent. Am J Pathol 155: 897-905.
43. Santiago FS, Ishii H, Shafi S, Khurana R, Kanellakis P, Bhindi R et al. (2007). Yin Yang-1 inhibits vascular smooth muscle cell growth and intimal thickening by repressing p21WAF1/Cip1 transcription and p21WAF1/Cip1-Cdk4-cyclin D1 assembly. Circ Res 101: 146-155.
44. Santiago FS, Lowe HC, Day FL, Chesterman CN, Khachigian LM (1999b). Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. Am J Pathol 154: 937-944.
45. Santiago FS, Lowe HC, Kavurma MM, Chesterman CN, Baker A, Atkins DG et al. (1999c). New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 5: 1264-1269.
46. Santoro SW, Joyce GF (1997). A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 94: 4262-4266.
47. Santoro SW, Joyce GF (1998). Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 37: 13330-13342.
48. Silverman ES, Khachigian LM, Santiago FS, Williams AJ, Lindner V, Collins T (1999). Vascular smooth muscle cells express the transcriptional corepressor NAB2 in response to injury. Am J Pathol 155: 1311-1317.
49. Skarlatos SI (2007). New programs for gene- and cell-based therapies at NHLBI. Clin Pharmacol Ther 82: 334-336.
50. Stein CA (1997). Controversies in the cellular pharmacology of oligodeoxynucleotides. Ciba Found Symp 209: 79-89; discussion 89-93.
51. Sun LQ, Cairns MJ, Gerlach WL, Witherington C, Wang L, King A (1999). Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme. J Biol Chem 274: 17236-17241.
52. Sun LQ, Cairns MJ, Saravolac EG, Baker A, Gerlach WL (2000). Catalytic nucleic acids: from lab to applications. Pharmacol Rev 52: 325-347.
53. Thiel G, Cibelli G (2002). Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193: 287-292.
54. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB et al. (1996). Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93: 704-711.
55. van Rooij E, Olson EN (2007). MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117: 2369-2376.
56. Vidal F, Aragones J, Alfranca A, de Landazuri MO (2000). Upregulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: role of transcription factor Egr-1. Blood 95: 3387-3395.
57. Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hokfelt T et al. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 97: 5633-5638.
58. Xiang G, Schuster MD, Seki T, Kocher AA, Eshghi S, Boyle A et al. (2004). Down-regulation of plasminogen activator inhibitor 1 expression promotes myocardial neovascularization by bone marrow progenitors. J Exp Med 200: 1657-1666.
59. Xiang G, Schuster MD, Seki T, Witkowski P, Eshghi S, Itescu S (2005a). Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularization and reduces cardiomyocyte apoptosis after acute myocardial infarction. J Am Coll Cardiol 46: 536-541.
60. Xiang G, Seki T, Schuster MD, Witkowski P, Boyle AJ, See F et al. (2005b). Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia. J Biol Chem 280: 39394-39402.
61. Yan SF, Fujita T, Lu J, Okada K, Shan Zou Y, Mackman N et al. (2000). Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 6: 1355-1361.
62. Yue P, Massie BM, Simpson PC, Long CS (1998). Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol 275: H250-H258.
63. Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ, Khachigian LM (2004). Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 96: 683-696.